RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.
Tirzepatide is a peptide studied as a dual agonist of the GIP and GLP-1 receptors. Independent research has examined this receptor profile in metabolic and endocrine studies.
Research background: In the SURMOUNT-1 study, Jastreboff et al. conducted a 72-week, Phase 3, double-blind randomized controlled trial involving 2,539 adults with obesity or overweight and a related complication, without diabetes. The trial evaluated body-weight change and adverse events using a sponsor-manufactured tirzepatide drug product. It did not evaluate any Amino Fusion Labs material.
Primary study: Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicin
SUPPLIED AS LYOPHILIZED POWDER. For qualified laboratory research only. Any preparation or handling must follow an authorized laboratory’s validated protocol. Not for human or veterinary use. No dosing, reconstitution, compounding, or administration instructions are provided.e (2022).
https://pubmed.ncbi.nlm.nih.gov/35658024/
This citation is provided solely as scientific background. It does not establish the identity, purity, quality, safety, effectiveness, FDA approval, or suitability of this product and is not a recommendation for human use.
This Amino Fusion Labs product has not been evaluated or approved by the U.S. Food and Drug Administration. It is not intended for ingestion, injection, inhalation, topical application, compounding, diagnostic use, therapeutic use, or any other administration to humans or animals. Amino Fusion Labs provides no medical advice, dosing guidance, reconstitution instructions, or administration instructions.
RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.
Tirzepatide is a peptide studied as a dual agonist of the GIP and GLP-1 receptors. Independent research has examined this receptor profile in metabolic and endocrine studies.
Research background: In the SURMOUNT-1 study, Jastreboff et al. conducted a 72-week, Phase 3, double-blind randomized controlled trial involving 2,539 adults with obesity or overweight and a related complication, without diabetes. The trial evaluated body-weight change and adverse events using a sponsor-manufactured tirzepatide drug product. It did not evaluate any Amino Fusion Labs material.
Primary study: Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicin
SUPPLIED AS LYOPHILIZED POWDER. For qualified laboratory research only. Any preparation or handling must follow an authorized laboratory’s validated protocol. Not for human or veterinary use. No dosing, reconstitution, compounding, or administration instructions are provided.e (2022).
https://pubmed.ncbi.nlm.nih.gov/35658024/
This citation is provided solely as scientific background. It does not establish the identity, purity, quality, safety, effectiveness, FDA approval, or suitability of this product and is not a recommendation for human use.
This Amino Fusion Labs product has not been evaluated or approved by the U.S. Food and Drug Administration. It is not intended for ingestion, injection, inhalation, topical application, compounding, diagnostic use, therapeutic use, or any other administration to humans or animals. Amino Fusion Labs provides no medical advice, dosing guidance, reconstitution instructions, or administration instructions.